Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
Share
Why It Matters
A stock expert thinks Camp4 Therapeutics is worth buying. They set a price goal of eight dollars to watch for.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.